Melanoma × Endocrine × 90 days × Clear all
NCT02568267 2026-05-27

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 1 FDA
NCT04284774 2026-05-27

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
5 enrolled 9 charts
NCT02012699 2026-05-05

iCaRe2

University of Nebraska

Recruiting
999,999 enrolled
NCT03050268 2026-04-23

SJFAMILY

St. Jude Children's Research Hospital

Recruiting
1,500 enrolled
NCT05461430 2026-04-13

TraveraRTGx

Travera Inc

Completed
72 enrolled
NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled